• Serdar Şahin, Özlem Haliloğlu, Özge Polat Korkmaz, Emre Durcan, Hümeyra Rekalı Şahin, Volkan Demirhan Yumuk, Taner Damcı, Hasan Mahmut İlkova, and Zeynep Oşar Siva.
• Department of Internal Medicine, Faculty of Medicine, İstanbul University-Cerrahpasa, İstanbul, Turkey
• Turk J Med Sci. 2020 Dec 28; 51 (2): 735-742.

Background/AimTo evaluate the impact of treatment with sodium-glucose co-transporter-2 (SGLT2) Inhibitors on quality of life (QoL), sleep quality (SQ), and anxiety levels in patients with Type 2 diabetes mellitus (T2DM).Materials And MethodsNinety-seven patients with type 2 diabetes admitted to tertiary care hospital diabetes clinic were included. Fifty patients were randomized to receive SGLT2 inhibitors in addition to baseline treatment (Group A), 47 subjects continued with their baseline treatment or were added other medications as needed (Group B). Thirty healthy controls (HC) were recruited (Group C). All groups were subjected to the Turkish version of Short Form-36 (SF-36), Pittsburgh Sleep Quality (PSQ), and Beck Anxiety Inventory (BAI) scales both at baseline and final visit.ResultsPhysical function, emotional role limitation, vitality, mental health, pain, general health perception scores of SF-36 were significantly improved in Group A, at the end of the follow-up period. There was no significant change in terms of PSQ, BAI scores, and hypoglycaemia documented in all groups. The intervention-related change in HbA1c level, body weight, and body mass index were significantly higher in Group A.ConclusionThe QoL was improved in people with diabetes who were taking SGLT2 inhibitors. This may be explained by weight loss observed in participants.This work is licensed under a Creative Commons Attribution 4.0 International License.

21 keywords...

hide…